Free shipping on all orders over $ 500

ALK Anaplastic lymphoma kinase

Cat.No.  Name Information
M2075 LDK378 LDK378 is a highly selective, orally bioavailable ALK inhibitor with IC50 of 0.15 nM.
M1950 ASP3026 ASP3026 is a novel and selective inhibitor for the ALK kinase.
M1873 LDN-193189 LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3.
M1794 SB431542 SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM).
M1743 X-376 X-376 is a potent and highly specific ALK small molecule tyrosine kinase inhibitor with IC50 of 0.61 nM.
M1720 AP26113 (Brigatinib) AP26113 (Brigatinib) is a highly potent ALK inhibitor with IC50 of 0.6 nM.
M31136 Conteltinib Conteltinib (CT-707) is a potent second-generation mesenchymal lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with antitumor activity for studies related to hepatocellular carcinoma (HCC).
M9397 MS4078 MS4078 is a PROTAC degrader of ALK which potently decreases cellular levels of oncogenic active ALK fusion proteins in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.
M6186 Repotrectinib (TPX-0005) Repotrectinib (TPX-0005) is a potential best-in-class ALK/ROS1/TRK inhibitor against SRC, wild-type WT ALK, The IC50 values of ALK G1202R and ALK L1196M were 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM, respectively.
M6168 Ceritinib (LDK378) dihydrochloride Ceritinib dihydrochloride (LDK378 dihydrochloride) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.
M5613 Entrectinib (RXDX-101) Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM.
M5320 Crizotinib hydrochloride Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK. Crizotinib inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM). Crizotinib is useful in treatment of anaplastic large-cell lymphoma.
M5309 ALK-IN-1 ALK-IN-1 is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.
M4984 CEP-37440 CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
M4811 CH5424802 HCl CH5424802 HCl is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.
M3975 Lorlatinib (PF-06463922) Lorlatinib (PF-06463922) is an oral active, selective, brain osmotic and ATP-competitive ROS1/ALK inhibitor. The Ki of Lorlatinib for ROS1, wild-type ALK and ALK(L1196M) were <0.025 nM, <0.07 nM and 0.7 nM, respectively. Lorlatinib has anticancer activity.
M3889 LDN-214117 LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM and >100 fold selectivity for ALK5.
M3781 NVP-TAE684 NVP-TAE684 is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC(50) values between 2 and 10 nM.
M2859 ML347 ML347 is a selective BMP receptor inhibitor with IC50 of 32 nM for ALK2, >300-fold selectivity over ALK3. Also inhibits ALK1 activity with IC50 of 46 nM.
M2806 LDN-212854 LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively.

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.